Genitourinary Cancer News

Immune checkpoint inhibitors may confer benefit to certain patients with advanced penile squamous cell carcinoma, according to retrospective study results.

Combining weight-based dosing and single-use vial sharing within individual Veterans Affairs hospitals could reduce immune checkpoint inhibitor spending by millions annually, according to study results published in Health Affairs.

Belzutifan prolonged PFS compared with everolimus for certain patients with advanced renal cell carcinoma, according to topline data released by the agent’s manufacturer.

Pembrolizumab added to twice weekly gemcitabine plus transurethral muscle-invasive urothelial cancer resection of a bladder tumor and hypofractionated radiation therapy appeared safe for patients with muscle-invasive urothelial cancer.

A presentation at ASCO Annual Meeting supported the use of first-line axitinib and pembrolizumab in the treatment of patients with advanced renal cell carcinoma.

Patients with muscle-invasive bladder cancer receiving dose-dense methotrexate, vinblastine, doxorubicin and cisplatinhad improved OS at 5 years compared with gemcitabine and cisplatin, according to a presentation at ASCO Annual Meeting.

A review of oncology trials showed approximately two-thirds did not report results on any of three key platforms within 1 year of completion.

The FDA announced several regulatory actions the past few weeks.

The University of Texas MD Anderson Cancer Center has retained its distinction as the No. 1 cancer hospital in the country.

Listening to music during chemotherapy infusion appeared to improve mood and reduce distress among a cohort of patients with cancer, according to study results published in JCO Oncology Practice.